右美托咪定或丙泊酚用于脓毒症机械通气成人患者的镇静
多中心双盲RCT纳入432例脓毒症机械通气成人,随机接受右美托咪定(0.2–1.5 μg/kg/h)或丙泊酚(5–50 μg/kg/min),床旁护士按RASS调整剂量至临床医生设定的轻镇静目标。主要终点14天干预期内无谵妄或昏迷存活天数两组无差异(校正中位数10.7 vs 10.8天;OR 0.96,95%CI 0.74–1.26)。28天无呼吸机天数、90天死亡、6个月TICS-T评分及安全性终点均无差异。提示在推荐轻镇静策略下,两种镇静剂对脓毒症机械通气患者结局等效。
要点
- 脓毒症机械通气成人轻镇静目标下,右美托咪定与丙泊酚14天无谵妄昏迷存活天数无差异(10.7 vs 10.8天;OR 0.96,95%CI 0.74–1.26)。
- 28天无呼吸机天数无差异(校正中位数23.7 vs 24.0天;OR 0.98,95%CI 0.63–1.51)。
- 90天死亡无差异(38% vs 39%;HR 1.06,95%CI 0.74–1.52)。
- 6个月TICS-T认知评分无差异(校正中位数40.9 vs 41.4;OR 0.94,95%CI 0.66–1.33)。
- 两组安全性终点相似;试验药物中位使用3.0天(IQR 2.0–6.0),中位RASS为-2.0(IQR -3.0至-1.0)。
适用人群与场景
- 纳入:脓毒症且接受机械通气的成人,按推荐轻镇静策略管理。
- 排除:原文未提及具体排除标准。
- 场景:多中心ICU(双盲随机对照试验)。
诊断标准与关键阈值
- 镇静目标由临床医生根据Richmond Agitation-Sedation Scale(RASS,评分范围-5[无反应]至+4[好斗])设定,床旁护士据此调整试验药物剂量;原文报告的中位RASS为-2.0(IQR -3.0至-1.0)。
- 主要终点为14天干预期内无谵妄或昏迷的存活天数。
处置流程与药物剂量
- 第一步:脓毒症机械通气成人按推荐轻镇静策略,由临床医生根据RASS设定镇静目标。
- 第二步:随机分配接受右美托咪定0.2–1.5 μg/kg/h或丙泊酚5–50 μg/kg/min。
- 第三步:床旁护士根据RASS目标调整试验药物剂量;原文报告右美托咪定中位剂量0.27 μg/kg/h、丙泊酚中位剂量10.21 μg/kg/min,中位用药3.0天(IQR 2.0–6.0)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心、双盲随机对照试验;432例随机,422例纳入分析(右美托咪定214例,丙泊酚208例)。
- 干预与对照:右美托咪定(0.2–1.5 μg/kg/h) vs 丙泊酚(5–50 μg/kg/min),床旁护士按RASS目标调整剂量。
- 主要终点:14天无谵妄或昏迷存活天数无差异(校正中位数10.7 vs 10.8天;OR 0.96,95%CI 0.74–1.26)。
- 关键次要终点:28天无呼吸机天数无差异(校正中位数23.7 vs 24.0天;OR 0.98,95%CI 0.63–1.51);90天死亡无差异(38% vs 39%;HR 1.06,95%CI 0.74–1.52);6个月TICS-T评分无差异(校正中位数40.9 vs 41.4;OR 0.94,95%CI 0.66–1.33)。
- 安全性终点两组相似。
证据类型、等级与局限
- 证据类型:多中心、双盲随机对照试验(RCT)。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未提及明确局限;设计上为多中心双盲RCT,样本量422例纳入分析。
对床旁实践的改变
- 在脓毒症机械通气成人采用推荐轻镇静策略时,右美托咪定与丙泊酚在主要结局上等效,选择可基于其他因素而非疗效差异。
- 适用人群:脓毒症机械通气成人,按RASS设定轻镇静目标。
- 不适用人群:原文未提及。
- 常见陷阱:原文未提及。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号Clinical.gov NCT01739933,由National Institutes of Health资助。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Guidelines currently recommend targeting light sedation with dexmedetomidine or propofol for adults receiving mechanical ventilation. Differences exist between these sedatives in arousability, immunity, and inflammation. Whether they affect outcomes differentially in mechanically ventilated adults with sepsis undergoing light sedation is unknown.
METHODS: In a multicenter, double-blind trial, we randomly assigned mechanically ventilated adults with sepsis to receive dexmedetomidine (0.2 to 1.5 μg per kilogram of body weight per hour) or propofol (5 to 50 μg per kilogram per minute), with doses adjusted by bedside nurses to achieve target sedation goals set by clinicians according to the Richmond Agitation-Sedation Scale (RASS, on which scores range from -5 [unresponsive] to +4 [combative]). The primary end point was days alive without delirium or coma during the 14-day intervention period. Secondary end points were ventilator-free days at 28 days, death at 90 days, and age-adjusted total score on the Telephone Interview for Cognitive Status questionnaire (TICS-T; scores range from 0 to 100, with a mean of 50±10 and lower scores indicating worse cognition) at 6 months.
RESULTS: Of 432 patients who underwent randomization, 422 were assigned to receive a trial drug and were included in the analyses - 214 patients received dexmedetomidine at a median dose of 0.27 μg per kilogram per hour, and 208 received propofol at a median dose of 10.21 μg per kilogram per minute. The median duration of receipt of the trial drugs was 3.0 days (interquartile range, 2.0 to 6.0), and the median RASS score was -2.0 (interquartile range, -3.0 to -1.0). We found no difference between dexmedetomidine and propofol in the number of days alive without delirium or coma (adjusted median, 10.7 vs. 10.8 days; odds ratio, 0.96; 95% confidence interval [CI], 0.74 to 1.26), ventilator-free days (adjusted median, 23.7 vs. 24.0 days; odds ratio, 0.98; 95% CI, 0.63 to 1.51), death at 90 days (38% vs. 39%; hazard ratio, 1.06; 95% CI, 0.74 to 1.52), or TICS-T score at 6 months (adjusted median score, 40.9 vs. 41.4; odds ratio, 0.94; 95% CI, 0.66 to 1.33). Safety end points were similar in the two groups.
CONCLUSIONS: Among mechanically ventilated adults with sepsis who were being treated with recommended light-sedation approaches, outcomes in patients who received dexmedetomidine did not differ from outcomes in those who received propofol. (Funded by the National Institutes of Health; ClinicalTrials.gov number, NCT01739933.).
参考来源
- Hughes CG, Mailloux PT, Devlin JW, et al. Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. N Engl J Med. 2021. PMID: 33528922. doi:10.1056/NEJMoa2024922
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。